
|Articles|June 23, 2022
Daily Medication Pearl: Ketorolac Tromethamine Ophthalmic (Acuvail)
Author(s)Saro Arakelians, PharmD
Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.
Advertisement
Medication Pearl of the Day: Ketorolac Tromethamine Ophthalmic (Acuvail)
Indication: Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.
Insight:
- Dosing: One drop of Acuvail should be applied by the patient to the affected eye twice daily beginning 1 day prior to cataract surgery and continued through the first 2 weeks of the postoperative period.
- Dosage forms: Acuvail ophthalmic solution containing 4.5 mg/mL ketorolac tromethamine in a single-use vial. Thirty single-use vials filled with 0.4 mL of solution and 60 single-use vials filled with 0.4 mL of solution.
- Adverse events: Most common adverse reactions occurring in 1%-6% of patients were increased intraocular pressure, conjunctival hemorrhage, and blurred vision.
- Mechanism of action: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of Invasive Fungal Infections Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
5














































































































































































































